FDA approves Glenmark’s generic Glumetza extended-release tablets

The Food and Drug Administration has approved Glenmark Pharmaceuticals’ generic of Salix Pharmaceuticals Glumetza (metformin hydrochloride) extended-release tablets. Glenmark’s generic will be available in 500- and 1000-mg dosage strengths. 

The drug is indicated in the management of Type 2 diabetes. 

The branded product saw sales of $226.7 million in the year ended September 2019, according to IQVIA data.